Non-Cochrane · DTA · PM41598757
Available Evidence on the Diagnostic Accuracy of Chemiluminescence for Detecting Dysplasia or Malignant Transformation in Oral Potentially Malignant Disorders (OPMDs): A Systematic Review and Meta-Analysis.
Esperouz Fariba, Lorusso Mauro, Troiano Giuseppe, et al. · Journal of clinical medicine · 2026 · PubMed · doi:10.3390/jcm15020815
Findings
11 findings
| Population | ||||
|---|---|---|---|---|
| Patients with oral potentially malignant disorders undergoing diagnostic evaluation | Chemiluminescence (ViziLite, ViziLite Plus) as adjunct | Histopathology (reference standard) | Pooled sensitivity for dysplasia or malignant transformation Single assessment against histopathology · Specialist and tertiary clinics · All OPMDs | Pooled sensitivity 0.82 [0.77, 0.86] GRADE not reported 13 studies · 334 participants |
| Patients with oral potentially malignant disorders undergoing diagnostic evaluation | Chemiluminescence (ViziLite, ViziLite Plus) as adjunct | Histopathology (reference standard) | Pooled specificity for dysplasia or malignant transformation Single assessment against histopathology · Specialist and tertiary clinics · All OPMDs | Pooled specificity 0.48 [0.44, 0.53] GRADE not reported 13 studies · 479 participants |
| Patients with oral potentially malignant disorders undergoing diagnostic evaluation | Chemiluminescence (ViziLite, ViziLite Plus) as adjunct | Histopathology (reference standard) | Pooled sensitivity for dysplasia or malignant transformation Single assessment against histopathology · Specialist and tertiary clinics · All OPMDs | Pooled sensitivity 0.85 [0.70, 0.93] GRADE not reported 13 studies · 334 participants |
| Patients with oral potentially malignant disorders undergoing diagnostic evaluation | Chemiluminescence (ViziLite, ViziLite Plus) as adjunct | Histopathology (reference standard) | Pooled specificity for dysplasia or malignant transformation Single assessment against histopathology · Specialist and tertiary clinics · All OPMDs | Pooled specificity 0.47 [0.26, 0.68] GRADE not reported 13 studies · 479 participants |
| Patients with oral leukoplakia undergoing diagnostic evaluation | Chemiluminescence (ViziLite, ViziLite Plus) as adjunct | Histopathology (reference standard) | Pooled sensitivity for dysplasia or malignant transformation Single assessment against histopathology · Specialist and tertiary clinics · Leukoplakia lesions only | Pooled sensitivity 0.88 [0.77, 0.94] GRADE not reported 5 studies · 156 participants |
| Patients with oral leukoplakia undergoing diagnostic evaluation | Chemiluminescence (ViziLite, ViziLite Plus) as adjunct | Histopathology (reference standard) | Pooled specificity for dysplasia or malignant transformation Single assessment against histopathology · Specialist and tertiary clinics · Leukoplakia lesions only | Pooled specificity 0.55 [0.36, 0.72] GRADE not reported 5 studies · 130 participants |
| Patients with oral leukoplakia undergoing diagnostic evaluation | Chemiluminescence (ViziLite, ViziLite Plus) as adjunct | Histopathology (reference standard) | Pooled sensitivity for dysplasia or malignant transformation Single assessment against histopathology · Specialist and tertiary clinics · Leukoplakia lesions only | Pooled sensitivity 0.87 [0.80, 0.91] GRADE not reported 5 studies · 156 participants |
| Patients with oral leukoplakia undergoing diagnostic evaluation | Chemiluminescence (ViziLite, ViziLite Plus) as adjunct | Histopathology (reference standard) | Pooled specificity for dysplasia or malignant transformation Single assessment against histopathology · Specialist and tertiary clinics · Leukoplakia lesions only | Pooled specificity 0.51 [0.42, 0.59] GRADE not reported 5 studies · 130 participants |
| Patients with oral potentially malignant disorders undergoing diagnostic evaluation | Chemiluminescence: ViziLite | Histopathology (reference standard) | Diagnostic accuracy for dysplasia or malignant transformation Single assessment against histopathology · Specialist and tertiary clinics · Device: ViziLite | Accuracy 0.62 GRADE not reported Studies not reported |
| Patients with oral potentially malignant disorders undergoing diagnostic evaluation | Chemiluminescence: ViziLite with Lugol iodine | Histopathology (reference standard) | Diagnostic accuracy for dysplasia or malignant transformation Single assessment against histopathology · Specialist and tertiary clinics · Device: ViziLite with Lugol iodine | Accuracy 0.82 GRADE not reported Studies not reported |
| Patients with oral potentially malignant disorders undergoing diagnostic evaluation | Chemiluminescence: ViziLite Plus | Histopathology (reference standard) | Diagnostic accuracy for dysplasia or malignant transformation Single assessment against histopathology · Specialist and tertiary clinics · Device: ViziLite Plus | Accuracy 0.53 GRADE not reported Studies not reported |
Included primary studies 13
Open in Studies| Study | Year | Also included by | Outcomes it informs here | Trial data |
|---|---|---|---|---|
| Mehrotra 2010 A cross-sectional study evaluating chemiluminescence and autofluorescence in the detection of clinically innocuous precancerous and… PMID:20123872 | 2010 | 1 other review | Pooled specificity for dysplasia or malignant transformation | not extracted yet |
| Awan 2011 Utility of chemiluminescence (ViziLite™) in the detection of oral potentially malignant disorders and benign keratoses. PMID:21615500 | 2011 | this review only | Pooled specificity for dysplasia or malignant transformation | not extracted yet |
| Chaudhry 2014 Evaluation of efficacy of chemiluminescence for diagnosis of leukoplakia DOI:10.1016/s1348-8643(14)00004-4 | 2014 | this review only | Pooled specificity for dysplasia or malignant transformation | not extracted yet |
| Chaudhry 2016 Comparison of chemiluminescence and toluidine blue in the diagnosis of dysplasia in leukoplakia: a cross-sectional study. PMID:25532724 | 2016 | this review only | Pooled specificity for dysplasia or malignant transformation | not extracted yet |
| Farah 2007 A pilot case control study on the efficacy of acetic acid wash and chemiluminescent illumination (ViziLite) in the visualisation of oral… PMID:17169603 | 2007 | this review only | Pooled specificity for dysplasia or malignant transformation | not extracted yet |
| Kaemmerer 2015 A chemiluminescent light system in combination with toluidine blue to assess suspicious oral lesions-clinical evaluation and review of the… PMID:24888605 | 2015 | this review only | Pooled specificity for dysplasia or malignant transformation | not extracted yet |
| Mojsa 2012 Value of the ViziLite Plus System as a diagnostic aid in the early detection of oral cancer/premalignant epithelial lesions. PMID:22446458 | 2012 | this review only | Pooled specificity for dysplasia or malignant transformation | not extracted yet |
| Rajmohan 2012 Assessment of oral mucosa in normal, precancer and cancer using chemiluminescent illumination, toluidine blue supravital staining and oral… PMID:23248459 | 2012 | this review only | Pooled specificity for dysplasia or malignant transformation | not extracted yet |
| Ram and Siar 2005 Chemiluminescence as a diagnostic aid in the detection of oral cancer and potentially malignant epithelial lesions. PMID:16053872 | 2005 | this review only | Pooled specificity for dysplasia or malignant transformation | not extracted yet |
| Sharma 2011 Non-invasive diagnostic tools in early detection of oral epithelial dysplasia DOI:10.4317/jced.3.e184 | 2011 | this review only | Pooled specificity for dysplasia or malignant transformation | not extracted yet |
| Shukla 2018 Comparative efficacy of chemiluminescence and toluidine blue in the detection of potentially malignant and malignant disorders of the oral… PMID:30651697 | 2018 | this review only | Pooled specificity for dysplasia or malignant transformation | not extracted yet |
| Swathi 2021 Comparing the efficacy of chemiluminescence with lugol's iodine versus toluidine blue in the diagnosis of dysplasia in tobacco associated… PMID:35645072 | 2021 | this review only | Pooled specificity for dysplasia or malignant transformation | not extracted yet |
| Torres 2013 Efficacy of Chemiluminescence (ViziLite™) as a Screening Method in the Detection of Clinically Suspicious Oral Cancerous and Precancerous… DOI:10.6000/1927-7229.2013.02.03.8 | 2013 | this review only | Pooled specificity for dysplasia or malignant transformation | not extracted yet |
Overlap with other reviews
Reviews that include the same primary studies are not independent evidence. Shared counts match studies by PMID, DOI or NCT, and otherwise by author and year (a probable match). Only the non-Cochrane dental reviews have study lists, so overlap with Cochrane reviews is not counted yet.
| Review | Shared studies | Jaccard |
|---|---|---|
| Diagnostic efficacy of VELscope in oral potentially malignant disorders: a systematic review and meta-analysis. (2026) | 1 | 0.03 |
Review question
| Element | Planned (methods) | Found (results) |
|---|---|---|
| Population | Patients with oral potentially malignant disorders (including leukoplakia) undergoing diagnostic evaluation for dysplasia or malignant transformation | OPMD patients or lesions (13 studies); leukoplakia subgroup (5 studies) |
| Intervention | Chemiluminescence-based devices (ViziLite, ViziLite Plus, ViziLite with toluidine blue or Lugol) as index test | ViziLite, ViziLite Plus, ViziLite with Lugol iodine, often with toluidine blue (13 studies) |
| Comparison | Histopathological examination of biopsied lesions (reference standard) | Histopathology (13 studies) |
| Outcomes | Sensitivity, specificity, diagnostic odds ratio, SROC curve performance | Pooled sensitivity 0.82 and specificity 0.48 (all OPMD); sensitivity 0.87 and specificity 0.51 (leukoplakia); device accuracy |
| Study designs | Prospective and retrospective clinical studies with extractable 2x2 data; English full texts | Cross-sectional or diagnostic accuracy studies (13) |
| Timing | Not specified | Not specified |